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Background: Basic studies have shown that glucagon-like peptide-1 (GLP-1) analogs exert a direct protective effect on
the vascular endothelium in addition to their indirect effects on postprandial glucose and lipid metabolism. GLP-1
analogs are also reported to inhibit postprandial vascular endothelial dysfunction. This study examined whether the
GLP-1 analog exenatide inhibits postprandial vascular endothelial dysfunction in patients with type 2 diabetes
mellitus (T2DM).
Methods: Seventeen patients with T2DM underwent a meal tolerance test to examine changes in postprandial
vascular endothelial function and in glucose and lipid metabolism, both without exenatide (baseline) and after a single
subcutaneous injection of 10 μg exenatide. Vascular endothelial function was determined using reactive hyperemia
index (RHI) measured by peripheral arterial tonometry before and 120 min after the meal loading test. The primary
endpoint was the difference in changes in postprandial vascular endothelial function between the baseline and
exenatide tests.
Results: The natural logarithmically-scaled RHI (L_RHI) was significantly lower after the baseline meal test but not in the
exenatide test. The use of exenatide resulted in a significant decrease in triglycerides (TG) area under the curve and
coefficient of variation (CV). The change in L_RHI correlated with changes in CV of triglycerides and HDL-cholesterol.
Multivariate analysis identified changes in triglyceride CV as the only determinant of changes in L_RHI, contributing to
41% of the observed change.
Conclusions: Exenatide inhibited postprandial vascular endothelial dysfunction after the meal loading test, suggesting
that exenatide has a multiphasic anti-atherogenic action involving not only glucose but also lipid metabolism.
Trial registration: ClinicalTrials.gov: UMIN000015699.
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Patients with type 2 diabetes mellitus (T2DM) are at
high risk for development of life-threatening atheroscler-
otic disease compared with healthy persons. For ex-
ample, the risk of coronary artery disease is 2.0 times
higher, and the risk of cerebral infarction is 2.3 times
higher in these patients [1]. It is presumed that vascular
endothelial dysfunction precedes clinically-evident dia-
betic macrovasculopathy [2] and that the former is due
to various factors such as abnormal glucose and lipid* Correspondence: tanaka@med.uoeh-u.ac.jp
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unless otherwise stated.metabolism, inflammation, hypertension, obesity, sedentary
life style, smoking, high salt intake, and menopause [3].
Among these factors, it seems that postprandial changes in
glucose and lipid metabolism are particularly important
risk factors for vascular endothelial dysfunction [4].
Both clinical and experimental evidences suggest that
oxidative stress and hypercytokinemia are associated
with postprandial hyperglycemia [5] and that post-
prandial hyperlipidemia enhances the progression of
atherosclerosis in patients with T2DM [6]. Therefore, cor-
rection of postprandial metabolic disorders and inhibition
of vasculopathy through the above pathways could poten-
tially prevent the progression of atherosclerosis.al. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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only indirectly correct postprandial glucose and lipid
metabolism [7], but they also inhibit vascular endothe-
lial dysfunction by their direct protective effects on the
vascular endothelium, such as enhancement of nitric
oxide (NO) production [8] and anti-inflammatory ac-
tion [9]. In actual clinical settings, long-term adminis-
tration of sitagliptin is reported to improve vascular
endothelial function [10] and exert anti-arteriosclerosis
action [11]. Clinically, glucagon-like peptide-1 (GLP-1) re-
ceptor agonists are known to improve pro-atherosclerosis
factors, such as glucose metabolism, lipid metabolism,
blood pressure, and body weight and that their long-term
effects include improvement of vascular endothelial func-
tion. In addition, one study reported that continuous
intravenous infusion of GLP-1 resulted in short-term,
blood glucose-independent improvement of vascular
endothelial dysfunction [12]. To our knowledge, only a
few studies have verified the effects of GLP-1 receptor
agonists on postprandial vascular endothelial dysfunc-
tion in daily clinical practice, and only little is known at
present on the mechanism of the inhibitory effects of
these drugs on vascular endothelial dysfunction. The
present study examined the effects of exenatide, a GLP-1
receptor agonist, on postprandial vascular endothelial
dysfunction after meal loading test in Japanese patients
with T2DM.Methods
Study subjects
This study included 17 patients with T2DM who were
admitted to the University of Occupational and Envir-
onmental Health Hospital (UOEH) or Wakamatsu
Hospital of UOEH between June 2011 and February 2014
and who met the following inclusion criteria: 1) age 20 to
less than 80 years; 2) no change in treatment with oral
glucose-lowering agents, lipid-lowering agents, and
anti-hypertensive agents during the 12 weeks preceding
enrollment; and 3) ongoing treatment by diet regimen
alone or by therapy with sulfonylurea, sulfonylurea plus
biguanide, or sulfonylurea plus thiazolidine derivatives.
Patients who met any of the following criteria were ex-
cluded from the study: 1) treatment of diabetes with in-
sulin; 2) experience of episodes of diabetic ketoacidosis,
nonketotic hyperosmolar coma, infection, or acute cor-
onary syndrome; 3) pregnancy or possible pregnancy;
4) history of stroke or ischemic heart disease within the
preceding 6 months; 5) history of pancreatitis; and
6) cardiac arrhythmia.
This study was approved by the ethics committee of
the UOEH, and the subjects received written informa-
tion about the study and gave consent to participate in
the study.Study design
All 17 patients with T2DM were admitted to the hospital
and underwent meal tolerance test to examine changes
in postprandial endothelial function and changes in glu-
cose and lipid metabolism (day 1). The test was repeated
the next day 15 min after subcutaneous injection of
10 μg exenatide (Byetta®; AstraZeneca K.K., Osaka,
Japan) (day 2). Both tests were carried out early in the
morning after 12 h of fasting. With regard to the meal
tolerance test, a test meal (total 450 kcal; 51.4% carbo-
hydrate, 33.3% fat, and 15.3% protein, a recipe proposed
by a working group of the Japan Diabetes Society) [13]
was used, and blood was analyzed before and 30, 60, 120,
and 240 min after meal loading to evaluate changes in glu-
cose and lipid metabolism. In addition, vascular endothe-
lial function was evaluated before and 120 min after meal
loading, using a peripheral arterial tonometry (PAT)
device (EndoPAT2000; Itamar Medical, Caesarea, Israel).
The evaluation items related to glucose metabolism
included plasma glucose and plasma immunoreactive in-
sulin (IRI). The evaluation items related to lipid metabol-
ism were triglycerides, high-density lipoprotein cholesterol
(HDL-C), and low-density lipoprotein cholesterol (LDL-C).
The area under the curve (AUC) and the coefficient of
variation (CV) were calculated for plasma glucose and IRI
based on data obtained at 5 measurement points from 0 to
240 min. The primary endpoint was changes in vascular
endothelial function at 0 and 120 min after meal loading
test conducted after exenatide, relative to the control (test
without exenatide).
Noninvasive vascular function test
The PAT-based method used for digital assessment of
vascular function has been described in detail previously
[14]. After an acclimatization period 30 min in a room
controlled for temperature and light in the fasting state,
the baseline pulse amplitude was recorded during a
period of 5 min before the induction of ischemia. The
latter was induced by placing the sphygmomanometer
cuff on the upper arm, while the opposite arm served as
a control. The PAT probes were placed on one finger of
each hand. After 5 min, the blood pressure cuff was
inflated to 60 mmHg above the systolic pressure or
200 mmHg for 5 min and then deflated to induce react-
ive hyperemia. As a measure of reactive hyperemia, the
reactive hyperemia index (RHI) was calculated as the
ratio of the average amplitude of the PAT signal over
1 min beginning 1.5 min after cuff deflation (control
arm, A; occluded arm, C) divided by the average ampli-
tude of the PAT signal over the 2.5-min time period be-
fore cuff inflation (baseline) (control arm, B; occluded
arm, D). Thus, RHI = (C/D)/(A/B) × baseline correction.
Because RHI has a heteroscedastic error structure, we
used natural logarithm transformation in all analyses.
Table 1 Baseline characteristics
Age (years) 53.2 ± 2.6
Gender (male/female) 13/2
Body mass index (kg/m2) 27.1 ± 1.5











Lipid-lowering drugs 4 (26.7)
Antihypertensive drugs 5 (48.8)
Current smokers 9 (60.0)
Cardiovascular disease 2 (13.3)
Systolic blood pressure (mmHg) 127.4 ± 4.3
Diastolic blood pressure (mmHg) 80.6 ± 3.3
LDL-C (mg/dL) 119.5 ± 9.3
HDL-C (mg/dL) 45.7 ± 3.5
Triglycerides (mg/dL) 153.0 ± 9.5
HbA1c (%) 9.5 ± 0.4
Fasting plasma glucose (mg/dL) 153.0 ± 9.5
Immunoreactive insulin (μU/mL) 7.4 ± 1.1
HOMA-IR 2.8 ± 0.5
HOMA-β 32.2 ± 5.7
C-peptide in urine (μg/day) 101.2 ± 18.8
L_RHI 0.54 ± 0.04
Data are mean ± SE, n, or n (%). n = 15.
Abbreviations: LDL-C low-density lipoprotein cholesterol, HDL-C high-density
lipoprotein cholesterol, TG triglycerides, HbA1c hemoglobin A1c, HOMA-IR
homeostasis model assessment as an index of insulin resistance, HOMA-β
homeostasis model assessment beta cell function, L_RHI the natural
logarithmic scaled reactive hyperemia index.
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serum lipids
Blood samples were collected early in the morning after
at least 12-h fasting, through a venous line placed in the
median vein using an indwelling catheter. Plasma lipid
was measured with a Hitachi 7350 autoanalyzer (Hitachi
Co., Tokyo, Japan). HDL-C, and triglycerides levels were
determined by using an enzymatic method, and both
enzymatic method and direct technique were used for
LDL-C. The insulin resistance index (homeostasis
model assessment of insulin resistance) was calculated
according to the formula: fasting IRI (mU/L) × fasting
glucose (mg/dL)/405. Hemoglobin Alc (HbA1c) was mea-
sured by high-pressure liquid chromatography using the
Tosoh HLC-723 G8 (Tosoh Co., Kyoto, Japan). The
HbAlc level was obtained as a national glycohemoglobin
standardization program value by adding 0.4% to the value
expressed as the conventional Japanese standard substance
value [15].
Statistical analysis
Values are expressed as mean ± standard error.
Hypoglycemia, requiring glucose intake, developed in
two patients during the meal tolerance test after exena-
tide administration. Excluding these two patients, the
analysis included 15 patients. Wilcoxon’s signed rank
test was used to compare natural logarithmic-scaled RHI
(L_RHI) values at 0 or 120 min after the baseline and
exenatide meal loading tests. The Friedman test was
used to compare various parameters at 0, 30, 60, 120,
and 240 min after meal loading. Spearman’s correlation
method was used for analysis of the correlation between
L_RHI and changes in glucose metabolism or lipid me-
tabolism. Multivariate analysis used the difference be-
tween changes in L_RHI in the baseline and exenatide
meal tolerance tests as the dependent variable. The inde-
pendent variables were age, sex, body mass index (BMI),
disease duration, and differences between changes in
blood glucose AUC, changes in triglycerides CV, and
changes in HDL-C CV without exenatide compared with
exenatide administration. The step-up procedure was
used for this analysis. Statistical analyses were conducted
using SPSS Statistical Software version 19.0 (SPSS Inc.,
Chicago, IL), and the results were regarded as significant
when the p value was <0.05.
Results
Clinical characteristics
Table 1 shows the patient characteristics. Since the ad-
ministration of exenatide resulted in hypoglycemia in
two patients during the meal tolerance test, they were
excluded from the study. Thus, the study subjects were
15 patients with T2DM. The subjects were 15 patients
(13 men and 2 women) with a mean age of 53.2 ± 2.6(range, 35–71) years. They were mildly obese, with a
mean BMI of 27.1 ± 1.5 kg/m2. The mean duration of
diabetes mellitus was 7.0 ± 1.0 (range, 1–14) years. The
mean fasting plasma glucose was 153.0 ± 9.5 (range,
114–270) mg/dL, HbA1c was 9.5 ± 0.4% (range, 7.6–
13.7%), and the insulin level was 7.4 ± 1.1 (range, 2.2–16.2)
μU/mL. LDL-C was 119.5 ± 9.3 (range, 64–202) mg/dL,
HDL-C was 45.7 ± 3.5 (range, 29–86) mg/dL, and triglyc-
erides was 153.0 ± 9.5 (range, 105–286) mg/dL.
Thirteen of the 15 patients were on oral hypoglycemic
drugs: 1 on metformin monotherapy, 2 on metformin
plus sulfonylurea, and 10 on sulfonylurea monotherapy.
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eases, and 4 (26.7%) were on lipid-lowering agents.
The L_RHI was 0.54 ± 0.04 (range, 0.23-1.03), and
there was no significant sex-related difference in L_RHI.Postprandial changes in glucose metabolism and lipid
profile after meal tolerance test
Glucose metabolism dynamics and lipid metabolism
profile are shown in Figure 1 and Table 2. The baseline
meal tolerance test was followed by significant increases
in plasma glucose, IRI, and triglycerides (p < 0.001, each),
with peak values registered at 2 h (Figure 1). Further-
more, the test was followed by significant decreases in
LDL-C and HDL-C (p < 0.001, each), with a trough oc-
curring at 2 h after meal.
On the other hand, the exenatide meal tolerance test
was followed by a significant decrease in plasma glucose,
with a trough at 2 h after the test (p < 0.001). Further-
more, no postprandial increase was noted in triglycer-
ides, and the triglycerides values were significantly lower
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Figure 1 Serial change in plasma glucose (A), immunoreactive insulin (I
lipoprotein cholesterol (HDL-C) (D) and triglycerides (E) after meal loadi
without exenatide.the corresponding values after the baseline test (p <
0.001, each).
Table 2 compares the results of the two tests. Al-
though plasma glucose AUC was significantly lower after
the exenatide test than baseline meal load test (855 vs.
442 mg/dL⋅h, p = 0.001), the IRI AUC was not different
(97 vs. 85 μU/mL⋅h, p = 0.211). The exenatide meal test
resulted in significant improvement in triglycerides AUC
(617 vs. 476 mg/dL⋅h, p = 0.001) and triglycerides CV
(0.15 vs. 0.06, p = 0.001).
Postprandial changes in endothelial function after meal
tolerance test
Figure 2 shows changes in L_RHI after the test meal.
L_RHI was significantly lower after the baseline test
meal, compared with the value before the test (0.46 vs
0.54, p = 0.029). In comparison, exenatide prevented the
fall in L_RHI after the meal test (0.58 vs 0.56, p = 0.699).
In addition, there was no change in pre-meal RHI with-
out exenatide or with a single exenatide injection of
10 μg (0.54 vs. 0.56; P = 0.498). However, post-meal RHI
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RI) (B), low-density lipoprotein cholesterol (LDL-C) (C), high-density
ng tests, preceded by placebo or exenatide injection. #p < 0.05 vs.
Table 2 Change in glucose and lipid metabolism after meal loading tests, preceded by placebo (baseline) or exenatide
injection
Baseline Exenatide P value
Glucose metabolism variables
AUC of plasma glucose [(mg/dL) · hr] 855.4 ± 45.3 442.3 ± 26.4 0.001
CV of plasma glucose 0.19 ± 0.02 0.20 ± 0.01 0.776
AUC of IRI [(μIU/mL) · hr] 96.7 ± 18.5 84.6 ± 28.9 0.211
CV of IRI 0.49 ± 0.04 0.53 ± 0.05 0.427
Lipid metabolism variables
AUC of TG [(mg/dL) · hr] 616.8 ± 68.7 475.5 ± 45.7 0.001
CV of TG 0.14 ± 0.02 0.06 ± 0.02 0.001
AUC of HDL-C [(mg/dL) · hr] 171.8 ± 12.2 177.2 ± 13.4 0.064
CV of HDL-C 0.03 ± 0.003 0.03 ± 0.003 0.730
AUC of LDL-C [(mg/dL) · hr] 419.0 ± 35.1 436.3 ± 32.8 0.221
CV of LDL-C 0.03 ± 0.003 0.03 ± 0.003 0.875
Data are mean ± SEM.
Abbreviations: AUC area under the curve, CV coefficient of variation, IRI immunoreactive insulin, TG triglycerides, HDL-C high-density lipoprotein cholesterol,
LDL-C low-density lipoprotein cholesterol.
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(0.46 vs. 0.58; P = 0.020). Further analysis showed
that the changes in L_RHI after the baseline meal
loading test did not correlate with plasma glucose
AUC (r = −0.475, p = 0.074) or IRI AUC (r = 0.093,
p = 0.742), but correlated with triglycerides CV (r = −0.780,
p = 0.001).
Table 3 shows the relationship between changes in








Figure 2 Serial changes in endothelial function after meal
loading tests, preceded by placebo or exenatide injection.
L_RHI, natural logarithmic scaled reactive hyperemia index *p < 0.05
vs. baseline.in glucose and lipid metabolism. First, changes in L_RHI
correlated with changes in triglycerides CV (r = −0.727,
p = 0.003) and changes in HDL-C CV. Second, multivari-
ate analysis was performed using changes in L_RHI on the
baseline and exenatide meal tolerance tests as the
dependent variable, and age, sex, BMI, disease duration,
and changes in blood glucose AUC, triglycerides CV, and
HDL-C CV on the same tests as the independent vari-
ables. The results identified changes in triglycerides CV
on the two tests as the most significant contributor (con-
tribution ratio, 41%) to the changes in L_RHI (Table 4).
Discussion
The present study indicated that single-dose exenatide can
inhibit postprandial endothelial dysfunction in Japanese pa-
tients with T2DM. Furthermore, a single dose of exenatide
corrected abnormalities in postprandial lipid metabolism,
with particular improvement in postprandial hypertriglyc-
eridemia, which could explain the observed improvement
in postprandial vascular endothelial function. In fact, previ-
ous retrospective studies reported that exenatide inhibited
the onset of cardiovascular events in patients with T2DM
[16] and that liraglutide, another GLP-1 analog, improved
intima-media thickening of the carotid artery [17]. These
results suggest anti-atherosclerotic activity for members of
the GLP-1 family, in addition to their effects on vascular
endothelial function.
T2DM is known to be associated with impairment of
vascular endothelial function [1], which plays a major
role in atherosclerogenesis. Previous studies demon-
strated that even one meal can impair vascular endothe-
lial function in patients with T2DM [4,18]. This acute
vascular endothelial dysfunction is presumed to occur
Table 3 Correlation coefficients between dL_RHI and clinical markers of glycemia and various nonglycemic metabolic
variables
dAUCglucose dAUCIRI dAUCTG dAUCHDL dAUCLDL dCVglucose dCVIRI dCVTGTG dCVHDL dCVLDL
dAUCIRI −0.39
dAUCTG −0.02 0.17
dAUCHDL 0.40 0.33 -.0.06
dAUCLDL −0.10 0.60* 0.04 0.35
dCVglucose 0.06 0.39 −0.24 −0.12 0.50
dCVIRI −0.43 0.58* 0.29 0.02 0.37 0.35
dCVTG 0.39 0.09 −0.06 −0.13 0.27 0.37 0.14
dCVHDL 0.44 −0.26 −0.23 −0.46 −0.09 −0.30 0.01 0.64*
dCVLDL 0.35 0.35 −0.22 −0.42 −0.24 −0.24 −0.60* 0.14 0.38
dL_RHI −0.37 0.33 0.24 0.16 −0.17 −0.19 0.29 −0.73** −0.61* −0.33
Data are results of Spearman rank correlation. *P < 0.05, **P < 0.01.
Abbreviations: dAUC change in the area under the curve, IRI Immunoreactive insulin, LDL low-density lipoprotein cholesterol, HDL high-density lipoprotein
cholesterol, TG triglyceride, dCV change in the coefficient of variation, dL_RHI change in the natural logarithmic scaled reactive hyperemia index.
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endothelial cell adhesion factors following enhancement
of protein kinase C and nuclear factor κ-light-chain-
enhancer of activated B activity, consequence to post-
prandial hyperglycemia and/or postprandial lipemia [19].
However, the state of high oxidative stress in various
diseases, including chronic glucose and lipid metabolism
disorders, hypertension, and chronic kidney disease,
plays an important role in increasing the level of asym-
metrical dimethylarginine [20], which is considered the
main compound responsible for endothelial damage. In
this study, similar to the report of Koska et al. [21],
vascular endothelial dysfunction elicited by the test meal
improved by single-dose exenatide. Because vascular
endothelial dysfunction is a manifestation of early-stage
atherosclerosis [2], we suggest that the single dose of
exenatide used in this study successfully inhibited post-
prandial endothelial dysfunction.
It has been reported that GLP-1 receptors are
expressed in vascular endothelial cells [22] and it has
been reported to directly increase NO production and
inhibit the expressions of endothelial cell adhesionTable 4 Results of linear multivariate analysis with dL_RHI as
Variables Unstandardized coefficients Stand
B SE
Intercept −0.257 0.150
dCVTG −0.502 1.729 −0.64
dAUCglucose - - −0.20
Adjusted multiple R2 0.412
Multivariate stepwise regression analysis with dL_RHI as the dependent variable an
independent variables.
Abbreviations: dL_RHI change in the natural logarithmic scaled reactive hyperemia i
of variation, HDL high-density lipoprotein cholesterol, TG triglyceride, SE Standard efactors [23]. GLP-1 increases NO production to improve
the vasodilatory response [8]. In addition, GLP-1 is
reported to inhibit overexpression of hyperglycemia-
induced vascular cell adhesion molecule-1 in vascular
endothelial cells [9]. In actual clinical settings, DPP4 in-
hibitor sitagliptin has been reported to increase GLP-1
and inhibit the expressions of endothelial cell adhesion
factors such as intercellular adhesion molecule-1
(ICAM-1) and E-selectin [24], indicating GLP-1 has dir-
ect and short-term vasodilatory and anti-inflammatory
effects that result in improvement of vascular endothe-
lial function. These effects could, at least in part, explain
the improvement in vascular endothelial function ob-
served after in the present study after a single dose
of exenatide.
In this study, exenatide administered before the meal
loading test inhibited the postprandial increase in tri-
glycerides. Previous studies also showed that a single
dose of GLP-1 inhibits the postprandial rise in triglycer-
ides and free fatty acids in healthy persons [25] and
inhibits the postprandial rise in triglycerides and apoli-
poprotein B48 in patients with T2DM [26]. GLP-1 isthe dependent variable
ardized coefficients β t P
value
95% CI
−1.721 0.111 −0.584, 0.069
2 −2.901 0.013 −0.878, −1.249
3 −0.847 0.415 -
d age, gender, BMI, duration of the disease, dAUCglucose, dCVTG, dCVHDL as the
ndex, dAUC change in the area under the curve, dCV change in the coefficient
rror, CVD cardiovascular disease, 95% CI 95% confidence interval.
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biting apolipoprotein B48 production and triglycerides
absorption through direct action on the gastrointestinal
tract [7], and inhibits postprandial increase in triglycer-
ides by reducing the gastric emptying rate [27]. It is
presumed that the same mechanisms are involved in the
improvement of postprandial lipid abnormalities ob-
served in the present study.
Recent large-scale clinical studies have shown that
postprandial hypertriglyceridemia increases the risk of
cardiovascular events independent of other risk factors
of diabetes mellitus, hypertension, and lipid metabolism
during fasting [28,29]. On the other hand, it has been
reported that postprandial deterioration of vascular
endothelial function is associated with postprandial
hyperglycemia and hypertriglyceridemia [30]. Improve-
ment in vascular endothelial function after single-dose
administration of incretin analog alogliptin [31] or
exenatide [21] has also been reported to be related to
improvement in postprandial lipid abnormalities. In the
present study, postprandial hypertriglyceridemia corre-
lated with postprandial decrease in vascular endothelial
function, and improvement in postprandial vascular
endothelial function after exenatide correlated with
improvement in postprandial hypertriglyceridemia. One
possible mechanism for this improvement is inhibition
of oxidative stress and reduced expression of endothe-
lial cell adhesion factor through improvement in post-
prandial lipid abnormalities, leading to improvement in
vascular endothelial dysfunction. Such improvement
seems to be due to the indirect and short-term effects
of exenatide.
This study had certain limitations. First, it was an
open-label study covering a small sample size with
possible selection bias. It has been reported that GLP-1
formulations did not improve vascular endothelial
function in T2DM patients with severe obesity [32] or
vascular endothelial function in fasting [33]. Therefore,
the finding needs to be validated in a larger sample size
in the future. Second, the direct effect of GLP-1 on
inflammatory cytokines, adhesion factors, oxidative
stress factors, among others, and their effects on vas-
cular endothelial function, was not evaluated in this
study. Since GLP-1 formulations are known to sup-
press oxidative stress and inflammation and thus sup-
press vascular endothelial dysfunction [34]. Our results
showed that improvement in postprandial hyper-
triglyceridemia was responsible for 41% improvement
in postprandial vascular endothelial function, while the
remaining 59% was probably related to the direct effect of
GLP-1 on vascular endothelial function. Further studies
are required to examine the direct effects of GLP-1 on
vascular endothelial function that are independent of
improvement in glucose and lipid metabolism.Conclusions
Administration of a single dose of exenatide before the
meal loading test inhibited postprandial vascular endo-
thelial dysfunction in patients with T2DM, suggesting
multitude of activities in the anti-atherosclerotic effects
of exenatide.
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